Chiara Biosciences

Chiara Biosciences is revolutionizing Targeted Protein Degradation (TPD) with its proprietary CURE-PRO (Combinatorial Ubiquitination REal-time PROteolysis) platform. CURE-PROs are small-molecule degraders that self-assemble inside cells using novel linker chemistry—one molecule engages an E3 ligase and another engages the target protein. This approach enables oral administration, enhanced cell/tissue penetration, and central nervous system accessibility. Chiara’s unique combinatorial strategy supports a high-throughput, reusable platform for developing both an internal pipeline and collaborative solutions for strategic CURE-PRO development. See to learn more.